Protein nanoparticles as drug carriers in clinical medicine

Advanced Drug Delivery Reviews

Volumn 60, Issue 8, 2008, Pages 876-885

  Hawkins, Michael J ^a   Soon Shiong, Patrick ^a   Desai, Neil ^a  

^a Abraxis BioScience Inc   (United States)

Author keywords

Abraxane; Albumin; Docetaxel; gp60; nab Paclitaxel; Paclitaxel; Polyethoxylated castor oil; Polysorbate 80; Rapamycin; SPARC

Indexed keywords

DRUG DELIVERY; DRUG PRODUCTS; ONCOLOGY; PROTEINS; SOLVENTS;

ABRAXANE; DOCETAXEL; PACLITAXEL; POLYETHOXYLATED CASTOR OIL; RAPAMYCIN;

NANOPARTICLES;

ABI 008; ABI 009; ALBUMIN; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CORTICOSTEROID; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; EPOTHILONE DERIVATIVE; GEMCITABINE; HUMAN ALBUMIN; NANOPARTICLE; PACLITAXEL; POLYSORBATE 80; PREDNISONE; RAPAMYCIN; SOLVENT; TAXANE DERIVATIVE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CLINICAL MEDICINE; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HISTORY OF MEDICINE; HUMAN; INFECTION COMPLICATION; KERATOPATHY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MELANOMA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NANOTECHNOLOGY; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; OVARY CANCER; PARTICLE SIZE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ENGINEERING; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; PACLITAXEL;

EID: 42649132499     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.08.044     Document Type: Review

References (66)

1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer v2 (2007). http://www.nccn.org/professionals/physician_gls/default.asp http://www.nccn.org/professionals/physician_gls/default.asp
2. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 1561-1565
3. Rowinsky E.K., Cazenave L.A., and Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82 (1990) 1247-1259
4. Choy H. Taxanes in combined-modality therapy for solid tumors. Oncology (Huntingt) 13 (1999) 23-38
5. Hainsworth J.D. Practical aspects of weekly docetaxel administration schedules. Oncologist 9 (2004) 538-545
6. Horwitz S.B. Personal recollections on the early development of Taxol. J. Nat. Prod. 67 (2004) 136-138
7. ten Tije A.J., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42 (2003) 665-685
8. Bissery M.C. Preclinical pharmacology of docetaxel. Eur. J. Cancer 31A suppl 4 (1995) S1-S6
9. Singla A.K., Garg A., and Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235 (2002) 179-192
10. Vaishampayan U., Parchment R.E., Jasti B.R., and Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54 (1999) 22-29
11. Dye D., and Watkins J. Suspected anaphylactic reaction to Cremophor EL. BMJ 280 (1980) 1353
12. Gelderblom H., Verweij J., Nooter K., and Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37 (2001) 1590-1598
13. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker Jr. J.R., Van Echo D.A., Von Hoff D.D., and Leyland-Jones B. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 8 (1990) 1263-1268
14. Kloover J.S., den Bakker M.A., Gelderblom H., and van Meerbeeck J.P. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br. J. Cancer 90 (2004) 304-305
15. Volcheck G.W., and Van Dellen R.G. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann. Allergy, Asthma, & Immun. 80 (1998) 159-163
16. Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Lacatelli A., Bonadonna G., and Egorin M.J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13 (1995) 180-190
17. Millward M.J., Webster L.K., Rischin D., Stokes K.H., Toner G.C., Bishop J.F., Olver I.N., Linahan B.M., Linsenmeyer M.E., and Woodcock D.M. Phase I trial of Cremophor EL with bolus doxorubicin. Clin. Cancer Res. 4 (1998) 2321-2329
18. Holmes F.A., and Rowinsky E.K. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin. Oncol. 28 (2001) 8-14
19. Holmes F.A., Madden T., Newman R.A., Valero V., Theriault R.L., Fraschini G., Walters R.S., Booser D.J., Buzdar A.U., Willey J., and Hortobagyi G.N. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 14 (1996) 2713-2721
20. Webster L.K., Cosson E.J., Stokes K.H., and Millward M.J. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br. J. Cancer 73 (1996) 522-524
21. Authier N., Gillet J.P., Fialip J., Eschalier A., and Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res. 887 (2000) 239-249
22. Windebank A.J., Blexrud M.D., and de Groen P.C. Potential neurotoxicity of the solvent vehicle for cyclosporine. J. Pharmacol. Exp. Ther. 268 (1994) 1051-1056
23. Authier N., Gillet J.P., Fialip J., Eschalier A., and Coudore F. Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox. Res. 3 (2001) 301-306
24. Lorenz W., Schmal A., Schult H., Lang S., Ohmann C., Weber D., Kapp B., Luben L., and Doenicke A. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in Cremophor El and development of a compound with reduced toxicity. Agents Actions 12 (1982) 64-80
25. Gligorov J., and Lotz J.P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 suppl 2 (2004) 3-8
26. van Zuylen L., Verweij J., and Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19 (2001) 125-141
27. Piccart M.J., Klijn J., Paridaens R., Nooij M., Mauriac L., Coleman R., Awada A., Selleslags J., Van Vreckem A., and van Glabbeke M. Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC). Eur. J. Cancer 31A suppl 5 (1995) S75
28. Piccart M.J., Klijn J., Paridaens R., Nooij M., Mauriac L., Coleman R., Bontenbal M., Awada A., Selleslags J., Van Vreckman A., and Van Glabbeke M. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J. Clin. Oncol. 15 (1997) 3149-3155
29. Cortes J., and Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. The Oncologist 12 (2007) 271-280
30. Sparreboom A., van Zuylen L., Brouwer E., Loos W.J., de Bruijn P., Gelderblom H., Pillay M., Nooter K., Stoter G., and Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59 (1999) 1454-1457
31. Winer E.P., Berry D.A., Woolf S., Duggan D., Kornblith A., Harris L.N., Michaelson R.A., Kirshner J.A., Fleming G.F., Perry M.C., Graham M.L., Sharp S.A., Keresztes R., Henderson I.C., Hudis C., Muss H., and Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol. 22 (2004) 2061-2068
32. Purcell M., Neault J.F., and Tajmir-Riahi H.A. Interaction of Taxol with human serum albumin. Biochim. Biophys. Acta 1478 (2000) 61-68
33. Paal K., Muller J., and Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur. J. Biochem. 268 (2001) 2187-2191
34. John T.A., Vogel S.M., Tiruppathi C., Malik A.B., and Minshall R.D. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am. J. Physiol., Lung Cell. Mol. Physiol. 284 (2003) L187-L196
35. Minshall R.D., Tiruppathi C., Vogel S.M., and Malik A.B. Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem. Cell Biol. 117 (2002) 105-112
36. Vogel S.M., Minshall R.D., Pilipovic M., Tiruppathi C., and Malik A.B. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am. J. Physiol. Lung Cell. Mol. Physiol. 281 (2001) L1512-L1522
37. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., and Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin. Cancer Res. 12 (2006) 1317-1324
38. Desai N., Trieu V., Vao R., Frankel T., and Soon-Shiong P. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs Taxol. Presented at the 27th Annual San Antonio Breast Cancer Symposium (December 8-11 2004) San Antonio, Texas
39. Porter P.L., Sage E.H., Lane T.F., Funk S.E., and Gown A.M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43 (1995) 791-800
40. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., and Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8 (2002) 1038-1044
41. Kearns C.M. Pharmacokinetics of the taxanes. Pharmacotherapy 17 5 pt 2 (1997) 105S-109S
42. Mross K., Hollander N., Hauns B., Schumacher M., and Maier-Lenz H. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother. Pharmacol. 45 (2000) 463-470
43. Sparreboom A., Scripture C.D., Trieu V., Williams P.J., De T., Yang A., Beals B., Figg W.D., Hawkins M., and Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 11 (2005) 4136-4143
44. Ibrahim N.K., Samuels B., Page R., Doval D., Patel K.M., Rao S.C., Nair M.K., Bhar P., Desai N., and Hortobagyi G.N. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23 (2005) 6019-6026
45. Seidman A.D., Tiersten A., Hudis C., Gollub M., Barrett S., Yao T.J., Lepore J., Gilewski T., Currie V., and Crown J. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J. Clin. Oncol. 13 (1995) 2575-2581
46. Smith R.E., Brown A.M., Mamounas E.P., Anderson S.J., Lembersky B.C., Atkins J.H., Shibata H.R., Baez L., DeFusco P.A., Davila E., Tipping S.J., Bearden J.D., and Thirlwell M.P. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol. 17 (1999) 3403-3411
47. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., Buzdar A.U., Frye D.K., and Hortobagyi G.N. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83 (1991) 1797-1805
48. Reichman B.S., Seidman A.D., Crown J.P., Heelan R., Hakes T.B., Lebwohl D.E., Gilewski T.A., Surbone A., Currie V., and Hudis C.A. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 11 (1993) 1943-1951
49. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., and O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005) 7794-7803
50. Guan Z., Feng F., Li Q.L., Jiang Z., Shen Z., Yu S., Feng J., Huang J., Yao Z., and Hawkins M.J. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J. Clin. Oncol. 25 18S (2007) 1038
51. O'Shaughnessy J., Nag S., Calderillo-Ruiz G., Jordaan J., Llombart A., Pluzanska A., Pawlicki M., Reyes J.M., Sekhon J., and Albain K.S. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc. Am. Soc. Clin. Oncol. 22 (2003) 7
52. Paridaens R., Biganzoli L., Bruning P., Klijn J.G., Gamucci T., Houston S., Coleman R., Schachter J., Van V.A., Sylvester R., Awada A., Wildiers J., and Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol. 18 (2000) 724-733
53. Chan S., Friedrichs K., Noel D., Pinter T., Van B.S., Vorobiof D., Duarte R., Gil G.M., Bodrogi I., Murray E., Yelle L., von Minckwitz G., Korec S., Simmonds P., Buzzi F., Gonzalez M.R., Richardson G., Walpole E., Ronzoni M., Murawsky M., Alakl M., Riva A., and Crown J. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17 (1999) 2341-2354
54. Gradishar W., Krasnojon D., Cheporov S., Makhson A., Manikhas G., Clawson A., and Hawkins M.J. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 25 18S (2007) 1032
55. Moreno-Aspitia A., and Perez E.A. North Central Cancer Treatment Group N0531: Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin. Breast Cancer 6 (2005) 361-364
56. Roy V., LaPlant B.R., Gross G.G., Bane C.L., Palmieri F.M., and Perez E.A. North Central Cancer Treatment Group, NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC). J. Clin. Oncol. 25 18S (2007) 1048
57. Somer B.G., Schwartzberg L.S., Arena F., Epperson A., Fu D., and Fortner B.V. Phase II of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J. Clin. Oncol. 25 18S (2007) 1053
58. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., and Hawkins M.J. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 17 (2006) 1263-1268
59. Rizvi N.A., Riely G.J., Azzoli C.G., Miller V.A., Ng K.K., Fiore J., Chia G., Brower M., Heelan R., Hawkins M.J., and Kris M.G. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small cell lung cancer. J. Clin. Oncol. 26 (2008) 639-643
60. Reynolds C., Barrera D., Vu D.Q., Jotte R., Spira A.I., Weissman C.H., Boehm K.A., Llegbodu D., Pritchard S., and Asmar L. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25 18S (2007) 7610
61. Hawkins M.J., Manikhas G., Makhson A., Cheporov S., Orlov S., Yablonsky P., Bhar P., and Socinski M. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 25 18S (2007) 7659
62. Teneriello M.G., Tseng P.C., Crozier M., Encarnacion C., Hancock K., Messing M.J., Boehm K.A., Williams A., Llegbodu D., and Asmar L. Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J. Clin. Oncol. 25 18S (2007) 5525
63. Nyman D.W., Campbell K.J., Hersh E., Long K., Richardson K., Trieu V., Desai N., Hawkins M.J., and Von Hoff D.D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23 (2005) 7785-7793
64. Damascelli B., Patelli G.L., Lanocita R., Di T.G., Frigerio L.F., Marchiano A., Garbagnati F., Spreafico C., Ticha V., Gladin C.R., Palazzi M., Crippa F., Oldini C., Calo S., Bonaccorsi A., Mattavelli F., Costa L., Mariani L., and Cantu G. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am. J. Roentgenol. 181 (2003) 253-260
65. Hawkins M.J., Desai N., and Soon-Shiong P. Experience with ABI-007 (Abraxane) administered by intra-arterial infusion to patients with cancers of the head and neck. Presented at 23rd Annual Symposium of the Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow (November 2 2005) New York
66. Stinchcombe T.E., Socinski M.A., Walko C.M., O'Neil B.H., Collichio F.A., Ivanova A., Mu H., Hawkins M.J., Goldberg R.M., Lindley C., and Dees E.C. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother. Pharmacol. 60 (2007) 759-766